(3 Minutes Read)
The WHO in September approved an initial vaccine and announced a plan to provide vaccines, tests, and treatments to the most vulnerable people in the world’s poorest countries.
Moldiag, a Moroccan startup, is now developing kits for Mpox tests after the World Health Organization (WHO) declared the virus a global emergency in August. The WHO in September approved an initial vaccine and announced a plan to provide vaccines, tests, and treatments to the most vulnerable people in the world’s poorest countries.
But near the epicentre in eastern Congo’s South Kivu province, doctors still rely on experience and observations to diagnose patients in the absence of laboratory tests, taking people’s temperatures and looking for visible symptoms.
The WHO recommends all suspected cases be tested. However, most aren’t confirmed by laboratory tests due to a shortage of kits. Most of Congo’s 26 provinces don’t have laboratories capable of processing them. That makes it difficult to ascertain how the virus is spreading, a key mechanism to containing it, health officials say.
Read Also:
https://trendsnafrica.com/bilateral-trade-between-uk-and-morocco-hits-3-8-billion/
At his factory in Morocco, Abdeladim Moumem, Moldiag’s founder and Chief Scientific Officer, says the Moroccan-manufactured tests could help affordably remedy shortages. The test will cost less than USD 5, a ballpark cost fixed by WHO.
